Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 27;25(5):387-398.
doi: 10.1093/ijnp/pyac014.

Effect of Glucocorticoid and 11β-Hydroxysteroid-Dehydrogenase Type 1 (11β-HSD1) in Neurological and Psychiatric Disorders

Seetal Dodd  1   2 , David R Skvarc  1   3 , Olivia M Dean  1   4 , Anna Anderson  5 , Mark Kotowicz  1   5   6 , Michael Berk  1   2   4   7
Affiliations

Effect of Glucocorticoid and 11β-Hydroxysteroid-Dehydrogenase Type 1 (11β-HSD1) in Neurological and Psychiatric Disorders

Seetal Dodd et al. Int J Neuropsychopharmacol. .

Abstract

11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity is implicated as a moderator of the progression of multiple diseases and disorders in medicine and is actively subject to investigation as a therapeutic target. Here we summarize the mechanisms of the enzyme and detail the novel agents under investigation. Such agents modulate peripheral cortisol and cortisone levels in hypertension, type 2 diabetes, metabolic disorders, and Alzheimer's disease models, but there is mixed evidence for transduction into symptom management. There is inchoate evidence that 11β-HSD1 modulators may be useful pharmacotherapies for clinical improvement in psychiatry and neurology; however, more research is required.

Keywords: 11β-HSD1 inhibitors; clinical translation; glucocorticoids; neurological; psychiatric.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cortisol-cortisone interconversion via 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD).
See this image and copyright information in PMC

References

    1. Actinogen Medical Limited Trading as Actinogen Medical ACN, w. a. c. a. (2019a, 1 October 2019) Cognitive improvement demonstrated with Xanamem. https://actinogen.com.au/wp-content/uploads/2019/10/20191001-ASX-1979471....
    1. Actinogen Medical Limited Trading as Actinogen Medical ACN, w. a. c. a. (2019b, 7 May 2019) Phase II Alzheimer’s disease trial – result. https://actinogen.com.au/wp-content/uploads/2019/05/20190507-ASX-1927475....
    1. Adam EK, Quinn ME, Tavernier R, McQuillan MT, Dahlke KA, Gilbert KE (2017) Diurnal cortisol slopes and mental and physical health outcomes: a systematic review and meta-analysis. Psychoneuroendocrinology 83:25–41. - PMC - PubMed
    1. Adam TC, Hasson RE, Ventura EE, Toledo-Corral C, Le KA, Mahurkar S, Lane CJ, Weigensberg MJ, Goran MI (2010) Cortisol is negatively associated with insulin sensitivity in overweight Latino youth. J Clin Endocrinol Metab 95:4729–4735. - PMC - PubMed
    1. Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, Mikhailidis DP (2013) 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 62:21–33. - PubMed

Publication types

MeSH terms